Low-Temperature Adaptation of the Rana temporaria Gastrocnemius Muscle at the Onset of Anabiosis

Journal of Evolutionary Biochemistry and Physiology - A study of the effect of a seasonal decrease in ambient temperature on the composition of free amino acids and ninhydrin-positive secondary...     

Hepatic Insulin-Positive Cells and Major Transcription Factors (PDX1, MAFA,NGN3) in Rat Models of Type 1 and Type 2 Diabetes Mellitus

Journal of Evolutionary Biochemistry and Physiology - Due to a high occurrence of diabetes mellitus (DM) and its complications, insulin-positive cells detected in different organs are of great...     

Bioelectrical Impedance of the Rat Myocardium and Liver under Chronic Exposure to Doxorubicin

Journal of Evolutionary Biochemistry and Physiology - Changes in bioelectrical impedance of the myocardium and liver were revealed in male Wistar rats chronically exposed to doxorubicin....     

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

1. Download : Download high-res image (212KB)
2. Download : Download full-size image

     

Inhibition in the lamprey spinal cord]

Glycine and GABA play the role of inhibitory transmitters in the lamprey spinal cord. The mechanisms of action of both amino acids to the membrane receptors producing the postsynaptic inhibition as well as role and mechanism of GABA action producing the presynaptic inhibition are considered in this paper. The data concerned with morphological substrates of both type inhibitions are discussed.     

Chronic viral hepatitis C: management update

The management of chronic viral hepatitis C is evolving rapidly. Monotherapy with interferon, the accepted standard of treatment until recently, achieves only a modest sustained virological response rate of 15%. Combination treatment with alpha-2b interferon and ribavirin has been shown to increase sustained response rates to 40% in patients who have never been treated with interferon and to 50% in those who have relapsed following monotherapy with interferon. However, side effects, which have led to the discontinuation of combination treatment in a significant proportion of patients, must be carefully monitored. Treatment with interferon alpha-2b and ribavirin has now been approved in Canada, but the selection and monitoring of patients suitable for combination treatment requires special expertise. Although improvements in current therapeutic options may be possible with more frequent, higher doses or long-acting forms of interferon together with ribavirin, low sustained response rates (i.e., below 30%) for patients with hepatitis C virus genotype 1 emphasize the need for novel antiviral medications that will target the functional sites of the HCV genome.     

Prophylactic and curative effects of Bacopa monniera in gastric ulcer models.

Bacopa monniera Wettst. (BM, syn. Herpestis monniera L; Scrophulariaceae), is an Ayurvedic drug used as a rasayana. Its fresh juice was earlier reported to have significant antiulcerogenic activity. In continuation, methanolic extract of BM (BME) standardized to bacoside-A content (percentage-38.0 ± 0.9), when given in the dose of 10–50 mg/kg, twice daily for 5 days, showed dose-dependent anti-ulcerogenic on various gastric ulcer models induced by ethanol, aspirin, 2 h cold restraint stress and 4 h pylorus ligation. BME in the dose of 20 mg/kg, given for 10 days, twice daily showed healing effects against 50% acetic acid-induced gastric ulcers. Further work was done to investigate the possible mechanisms of its action by studying its effect on various mucosal offensive acid-pepsin secretion and defensive factors like mucin secretion, mucosal cell shedding, cell proliferation and antioxidant activity in rats. BME 20 mg/kg showed no effect on acid-pepsin secretion, increased mucin secretion, while it decreased cell shedding with no effect on cell proliferation. BME showed significant antioxidant effect per se and in stressed animals. Thus, the gastric prophylactic and curative effects of BME may be due to its predominant effect on mucosal defensive factors.